Brittany Bagley Sells 4,338 Shares of Axon Enterprise, Inc. (NASDAQ:AXON) Stock

Axon Enterprise, Inc. (NASDAQ:AXON) CFO Brittany Bagley sold 4,338 shares of the stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $378.95, for a total value of $1,643,885.10. Following the sale, the chief financial officer now owns 98,825 shares of the company’s stock, valued at approximately $37,449,733.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Axon Enterprise Stock Performance

NASDAQ AXON opened at $379.61 on Friday. The company has a market cap of $28.69 billion, a P/E ratio of 111.00, a P/E/G ratio of 9.69 and a beta of 0.94. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.52 and a current ratio of 2.88. The business’s 50 day moving average price is $338.92 and its 200-day moving average price is $314.35. Axon Enterprise, Inc. has a fifty-two week low of $189.12 and a fifty-two week high of $385.00.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.18. The firm had revenue of $504.00 million for the quarter, compared to the consensus estimate of $478.35 million. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The company’s revenue for the quarter was up 34.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.80 EPS. Sell-side analysts predict that Axon Enterprise, Inc. will post 1.79 earnings per share for the current year.

Hedge Funds Weigh In On Axon Enterprise

Large investors have recently modified their holdings of the stock. ING Groep NV increased its position in shares of Axon Enterprise by 9.3% during the 4th quarter. ING Groep NV now owns 9,643 shares of the biotechnology company’s stock valued at $2,491,000 after purchasing an additional 821 shares during the last quarter. Avantax Advisory Services Inc. boosted its holdings in Axon Enterprise by 0.8% during the 1st quarter. Avantax Advisory Services Inc. now owns 5,302 shares of the biotechnology company’s stock valued at $1,659,000 after acquiring an additional 40 shares during the period. GSA Capital Partners LLP purchased a new position in Axon Enterprise during the 1st quarter valued at $931,000. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in Axon Enterprise by 14.8% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 170,376 shares of the biotechnology company’s stock valued at $53,307,000 after acquiring an additional 22,013 shares during the period. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in Axon Enterprise by 21.7% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 9,153 shares of the biotechnology company’s stock valued at $2,693,000 after acquiring an additional 1,634 shares during the period. Institutional investors own 79.08% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on AXON shares. JMP Securities increased their target price on Axon Enterprise from $375.00 to $430.00 and gave the stock an “outperform” rating in a research report on Thursday. Robert W. Baird increased their target price on Axon Enterprise from $360.00 to $400.00 and gave the stock an “outperform” rating in a research report on Tuesday. Needham & Company LLC reiterated a “buy” rating and set a $400.00 target price on shares of Axon Enterprise in a research report on Wednesday, August 7th. Bank of America started coverage on Axon Enterprise in a research report on Wednesday, July 17th. They set a “buy” rating and a $380.00 target price for the company. Finally, Craig Hallum increased their target price on Axon Enterprise from $370.00 to $376.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $365.38.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.